PubMed RSS Feed - -An exploratory, open-label, investigator-initiated study of interleukin-17A (IL-17A) blockade in patients with moderate to severe papulopustular rosacea.

[rss]

Related Articles

An exploratory, open-label, investigator-initiated study of interleukin-17A (IL-17A) blockade in patients with moderate to severe papulopustular rosacea.

Br J Dermatol. 2020 May 04;:

Authors: Kumar AM, Chiou AS, Shih YH, Li S, Chang ALS

Abstract
Currently, few systemic medications are effective for rosacea.1 Recent research has shown elevation of interleukin (IL)-17A in rosacea.2,3 To assess if the IL-17A inhibitor,4, 5 secukinumab, could improve moderate to severe papulopustular rosacea (PPR), an exploratory, open-label, single-arm investigator initiated clinical trial in adults with moderate to severe PPR was performed after Stanford Human Subjects Panel approval.

PMID: 32364247 [PubMed - as supplied by publisher]

{url} = URL to article